Studying the effect of L-arginine on blood pressure and cognitive function

The effect of L-arginine on blood pressure and cognitive function of elderly patients with hypertension

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250520065820N1

Enrollment

Registered

2026-01-24

Start date

2026-01-30

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Hypertension. Condition 2: Cognitive Disorder. Essential (primary) hypertension Other degenerative diseases of nervous system, not elsewhere classified

Interventions

Intervention 1: Intervention group: They will receive one gram of L-arginine,made by Dana pharmaceutical company ,twice a day (after breakfast and dinner) for four weeks. Intervention 2: Control grou

Eligibility

Sex/Gender

All

Age

60 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age 60 to 75 years (young elderly) Primary hypertension diagnosed by a cardiologist (at least one year) Systolic blood pressure 140 to 160 and diastolic blood pressure 90 to 120 mmHg (grade 1 blood pressure) Mild to moderate Montreal Cognitive Assessment Test score (11 to 26)

Exclusion criteria

Exclusion criteria: Presence of neurodegenerative diseases History of anxiety disorders Left ventricular ejection fraction less than 25%, which will be measured by a cardiologist with an echocardiographic device Renal failure Taking drugs that affect nitric oxide synthesis (SSRI antidepressants, antioxidants vitamin C and vitamin E, NSAIDs, nitrates, calcium channel blockers including amilodipine and diltiazem) History of ischemic heart disease, transient ischemic attack, stroke, and peripheral arterial disease Smoking Patients with a history of delirium Having diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Blood pressure. Timepoint: Blood pressure assessment will be performed at 5 time points: before the intervention, 7 days after the intervention, 14 days after the intervention, 21 days after the intervention, 38 days and 40 days after the intervention. Method of measurement: With a Hein dial sphygmomanometer and a stethoscope.;Cognitive function. Timepoint: Patients' cognitive function is also assessed 3 times: initially (before the intervention begins), 28 days, and 40 days after the intervention. Method of measurement: Montreal Cognitive Performance Score Assessment Tool.	—

Measure

Time frame

Blood pressure. Timepoint: Blood pressure assessment will be performed at 5 time points: before the intervention, 7 days after the intervention, 14 days after the intervention, 21 days after the intervention, 38 days and 40 days after the intervention. Method of measurement: With a Hein dial sphygmomanometer and a stethoscope.;Cognitive function. Timepoint: Patients' cognitive function is also assessed 3 times: initially (before the intervention begins), 28 days, and 40 days after the intervention. Method of measurement: Montreal Cognitive Performance Score Assessment Tool.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Rezaei Moghadam

Khoram-Abad University of Medical Sciences

Rezaeimoghadamsomayeh616@gmail.com+98 66 3332 3717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026